PMID- 20084725
OWN - NLM
STAT- MEDLINE
DCOM- 20100216
LR  - 20221207
IS  - 2078-2101 (Print)
IS  - 2078-2101 (Linking)
IP  - 2
DP  - 2007 Jul
TI  - Neoadjuvant chemotherapy in locally advanced non-small cell lung cancer.
PG  - 55-64
AB  - OBJECTIVE: The objective of this study was to evaluate the role of neoadjuvant 
      chemotherapy in the treatment of locally advanced non small cell lung cancer 
      (NSCLC) followed by radiotherapy versus radiotherapy alone. MATERIAL AND METHODS: 
      Sixty nine patients were randomized to chemotherapy (group A) or radiotherapy 
      alone (group B). The induction chemotherapy consists of cisplatin (80 mg/m2) day 
      1 and Gemcitabine (1250 mg/m2), infusion day 1 and 8. Cycles were repeated every 
      3 weeks. Radiotherapy was given 4-6 weeks after chemotherapy to a dose of 60 
      Gy/30 fractions/6 weeks. RESULTS: A total of 66 patients were evaluable for 
      response; 34 in group A and 32 in group B. The overall response rate was 41.2% 
      for group A and 21.8% for group B (P < 0.5) but with no complete response 
      observed in either group. At a median follow up of 15 months, the overall 
      survival was 65% and median survival was 12 months for group A. However in group 
      B the overall survival at 15 months was 30% and the median survival was 9 nt (P < 
      0.001). Treatment toxicity in group A was mainly haemotological in 79% of 
      patients none of them was grade II or IV. Grade Nausea and vomiting was reported 
      in 73.5% of patients, grade I esophagitis in 5.8% of patients, grade I, radiation 
      pneumonitis in 26.4% of patients. Alopecia was observed in 29.4% of patients, 
      nephrotoxicity in 17.4%. Treatment toxicity in group B were generally less than 
      in group A but not statistically significant except fr grade III vomiting (15.6%) 
      and alopecia (0%). CONCLUSION: Combination chemotherapy of cisplatin and 
      gemcitabine is a tolerable and active induction chemotherapy regimen for patients 
      with locally advanced NSCLC. Sequential radiotherapy given after induction 
      chemotherapy is tolerable and offers a hope of improved locoregional control and 
      survival compared with radiotherapy alone.
FAU - Hamouda, W
AU  - Hamouda W
AD  - Department of Radiation Oncology, Faculty of Medicine, Zagazig University. 
      walledham63@hotmail.com
FAU - Dorgham, Y
AU  - Dorgham Y
FAU - Yosry, A
AU  - Yosry A
FAU - Abdel Wahab, M
AU  - Abdel Wahab M
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Kuwait
TA  - Gulf J Oncolog
JT  - The Gulf journal of oncology
JID - 101500911
RN  - 0W860991D6 (Deoxycytidine)
RN  - Q20Q21Q62J (Cisplatin)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Adenocarcinoma/*drug therapy/radiotherapy/secondary
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma, Large Cell/*drug therapy/radiotherapy/secondary
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/radiotherapy/secondary
MH  - Carcinoma, Squamous Cell/*drug therapy/radiotherapy/secondary
MH  - Cisplatin/administration & dosage
MH  - Combined Modality Therapy
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology/radiotherapy
MH  - Male
MH  - Middle Aged
MH  - *Neoadjuvant Therapy
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Remission Induction
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Gemcitabine
EDAT- 2007/07/01 00:00
MHDA- 2010/02/17 06:00
CRDT- 2010/01/21 06:00
PHST- 2010/01/21 06:00 [entrez]
PHST- 2007/07/01 00:00 [pubmed]
PHST- 2010/02/17 06:00 [medline]
PST - ppublish
SO  - Gulf J Oncolog. 2007 Jul;(2):55-64.